This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO faces slowing Wegovy and Ozempic momentum, pricing risks and fierce competition ahead of Q3 earnings.
NVONegative Net Change LLYPositive Net Change AMGNNegative Net Change VKTXPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
RXRX gears up for Q3 results as it refocuses its pipeline and collaboration-driven revenue strategy.
ANIPNegative Net Change CRSPNegative Net Change IMCRPositive Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?
by Sundeep Ganoria
CRISPR Therapeutics is likely to witness an earnings beat as Casgevy sales climb and new CAR-T and in-vivo programs advance.
VRTXNegative Net Change BEAMPositive Net Change NTLANegative Net Change CRSPNegative Net Change
biotechs crispr earnings gene-editing gene-therapy medical
Intellia Gears Up to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
NTLA's third-quarter results are likely to reflect progress on the CRISPR pipeline, with focus on ATTR studies and progress in HAE therapy filing.
REGNPositive Net Change ANIPNegative Net Change NTLANegative Net Change IMCRPositive Net Change
biotechs
Will These 5 Drug Bigwigs Surpass Q3 Earnings Forecasts?
by Kanishka Das
Let's look at five pharma and biotech companies, PFE, AMGN, AZN, VTRS and MRNA, which are scheduled to release their third-quarter 2025 results this week.
AZNPositive Net Change PFEPositive Net Change AMGNNegative Net Change MRNAPositive Net Change VTRSNegative Net Change
biotechs pharmaceuticals
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
by Ekta Bagri
ZYME, NKTR, ANIP, and PCRX are poised for potential Q3 earnings surprises as the biotech sector shows strong momentum.
NKTRPositive Net Change PCRXNegative Net Change ANIPNegative Net Change ZYMENegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised
by Zacks Equity Research
ABBV tops Q3 earnings and revenue estimates, driven by Rinvoq and Skyrizi gains, and lifts its 2025 EPS outlook.
RHHBYPositive Net Change JNJPositive Net Change ABBVPositive Net Change GMABNegative Net Change
biotechs earnings medical pharmaceuticals
Should You Buy, Hold, or Sell BDTX Stock Ahead of Q3 Earnings?
by Ekta Bagri
Black Diamond Therapeutics gears up for Q3 results as investors eye key silevertinib data and additional development plans.
AZNPositive Net Change JNJPositive Net Change BDTXPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
APLS shares plunge 31% despite topping Q3 earnings and revenue estimates, as gains were driven by a one-time Sobi payment.
BEAMPositive Net Change FOLDNegative Net Change ANIPNegative Net Change APLSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues
by Zacks Equity Research
Agios posts a narrower-than-expected third-quarter loss as Pyrukynd drives a 44% revenue rise, with potential label expansions on the horizon.
BEAMPositive Net Change AGIONegative Net Change ANIPNegative Net Change NTLANegative Net Change
biotechs earnings
Demographic Megatrend: Stocks Poised to Benefit From Global Aging
by Urmimala Biswas
Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.
BSXPositive Net Change AMGNNegative Net Change EWNegative Net Change OHINegative Net Change ABBVPositive Net Change CTRENegative Net Change ENSGNegative Net Change
biotechs cell-therapy gene-therapy genetics genomics healthcare hospitals medical medical-devices
ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales
by Zacks Equity Research
Alnylam's Q3 earnings and revenues surge past forecasts, powered by booming Amvuttra sales and a key milestone payment from Roche.
ALNYPositive Net Change RHHBYPositive Net Change BEAMPositive Net Change FOLDNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
GILD Q3 Earnings and Sales Beat Estimates, HIV and Livdelzi Sales Grow
by Zacks Equity Research
Gilead posts upbeat Q3 results on strong HIV and Livdelzi sales, but shares slip despite earnings and revenue beats.
GSKPositive Net Change ALKSPositive Net Change GILDPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake
by Zacks Equity Research
INSM shares jump 16% as Brinsupri's strong debut offset wider Q3 losses, lifting revenue 52% year over year.
ALKSPositive Net Change INSMNegative Net Change HOWLNegative Net Change
biotechs earnings medical
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?
by Ahan Chakraborty
CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.
PFEPositive Net Change TBPHNegative Net Change CRMDNegative Net Change VTRSNegative Net Change
biotechnology biotechs medical pharmaceuticals
BIIB Beats on Q3 Earnings & Sales, Stock Down on Lowered '25 EPS View
by Zacks Equity Research
Biogen's Q3 earnings and sales top estimates on strong drug demand, but shares slide after the company cuts its 2025 EPS forecast.
BIIBPositive Net Change RHHBYPositive Net Change SUPNPositive Net Change
biotechs earnings medical pharmaceuticals
Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook
by Zacks Equity Research
IONS' Q3 results top estimates as robust Tryngolza and Wainua sales drive revenue growth. The company raises its 2025 outlook for the third time this year.
AZNPositive Net Change NVSPositive Net Change BIIBPositive Net Change IONSNegative Net Change
biotechs earnings medical pharmaceuticals
Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down
by Zacks Equity Research
AMRN's third-quarter earnings fall short of expectations, but stronger U.S. Vascepa sales push revenues above estimates.
BEAMPositive Net Change AMRNPositive Net Change ANIPNegative Net Change CRMDNegative Net Change
biotechs earnings
BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View
by Zacks Equity Research
Bristol-Myers' strong Q3 results, powered by Opdivo, Reblozyl and Breyanzi, led to a revenue guidance boost despite legacy drug declines.
BMYPositive Net Change PFEPositive Net Change ALKSPositive Net Change BNTXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Biotech ETFs Hovering Around a 52-Week: Here's Why
by Sanghamitra Saha
Biotech is back! Regulatory tailwinds, cheaper valuations, and Fed cut hopes are boosting ETFs like XBI and IBB. Is the rebound just starting?
IBBPositive Net Change SPYNegative Net Change BBCPositive Net Change XBIPositive Net Change SBIOPositive Net Change BBPPositive Net Change
biotechs etfs
Zoetis Gears Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
ZTS is poised for another earnings beat as rising demand for companion animal products like Simparica Trio and Apoquel drives expected Q3 revenue growth.
ALNYPositive Net Change VRTXNegative Net Change ZTSNegative Net Change EXASNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised
by Zacks Equity Research
ALKS tops Q3 earnings and revenue estimates as Vivitrol, Aristada and Lybalvi fuel growth; 2025 guidance raised after strong demand.
ALKSPositive Net Change ANIPNegative Net Change AVDLNegative Net Change HOWLNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View
by Zacks Equity Research
GSK's Q3 earnings and revenue beat expectations, powered by HIV and oncology growth, prompting the company to lift its 2025 outlook.
GSKPositive Net Change JNJPositive Net Change VIRNegative Net Change
biotechs earnings medical pharmaceuticals vaccines
RGEN'S Q3 Earnings Beat Estimates, Revenues Surge Y/Y, Stock Down
by Zacks Equity Research
Repligen posts strong Q3 results with revenue growth and an earnings beat, yet shares dip as tighter EPS guidance tempers investor optimism.
BEAMPositive Net Change RGENNegative Net Change ANIPNegative Net Change CRMDNegative Net Change
biotechs earnings
Should You Buy, Hold, or Sell GILD Stock Ahead of Q3 Earnings?
by Zacks Equity Research
Gilead Sciences gears up for Q3 results with strong HIV gains and new FDA approvals, amid challenges in its Cell Therapy business.
GSKPositive Net Change MRKPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals